KRAS and non-small cell lung carcinoma: A potential benefit in survival produced by erlotinib in K-RAS mutated NSCLC has been reported in the SATURN trial, a large phase III trial randomizing 889 patients who did not progress after first-line chemotherapy, to receive erlotinib or placebo as maintenance treatment [14, 48].